A series of novel 2-hydrazinyl-4-morpholinothieno[3,2-d]pyrimidine derivatives was designed and synthesized. All of them were screened for their cytotoxic activities against large cell lung cancer(H460), colon cancer (HT-29) and adenocarcinomic lung cancer(A549) cell lines in vitro. The pharmacological results indicate that most of the target compounds show moderate to significant activities. Especially compound 17 exhibits the most potent antitumor activities against H460, HT-29 and A549 cell lines with IC50 values of 0.57, 0.45 and 1.45 μmol/L, respectively.

Novel 4-morpholinothieno[3,2-d]pyrimidine derivatives show moderate to significant antitumor activities, with compound 17 showing the most potent antitumor activity against H460, HT-29, and A549 cell lines.

Paper

Synthesis and antitumor activities of novel 4-morpholinothieno[3,2-d]pyrimidine derivatives

References

Citations